FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204614968> ?p ?o ?g. }

• W3204614968 endingPage "100578" @default.
• W3204614968 startingPage "100578" @default.
• W3204614968 abstract "The concept of treatment of an allergy with the offending allergen was introduced more than a century ago. Allergen immunotherapy (AIT) is the only disease modifying treatment of allergic diseases caused by inhalational allergens and insect venoms. Despite this, only few AIT products have reached licensure in the US or an official marketing authorization status in European countries. Moreover, most of these AIT products are provided on an individual patient basis as named patient products (NPP) in Europe, while individualized preparations of (mixed) allergenic extract vials for subcutaneous administration (compounding) is common practice in the US. AIT products are generally considered safe and well tolerated, but the major practical clinical development challenge is to define the optimal dose and prove the efficacy and safety of these products using state-of-the art Phase II and pivotal Phase III studies. In planning Phase II-III AIT studies, a thorough understanding of the study challenges is essential (e.g. variability and non-validated status of subjective primary endpoints, limitations of pollen season definitions) and dogmas of these products (e.g., for sublingual immunotherapy (SLIT) trials double-blinding conditions cannot be maintained, resulting in stronger placebo responses in the active treatment group and inflated treatment effects in Phase III). There is future promise for more objective biomarker endpoints (e.g. basophil activation (CD63 and CD203c), subsets of regulatory dendritic, T and B cells, IL-10-producing group 2 innate lymphoid cells; alone or in combination) to overcome several of these dogmas and challenges; innovation in AIT clinical trials can only progress with integral biomarker research to complement the traditional endpoints in Phase II-III clinical development. The aim of this paper is to provide an overview of these dogmas, challenges and recommendations based on published data, to facilitate the design of Phase III studies and improve the evidence basis of safe and effective AIT products." @default.
• W3204614968 created "2021-10-11" @default.
• W3204614968 creator A5006632216 @default.
• W3204614968 creator A5006791916 @default.
• W3204614968 creator A5010870367 @default.
• W3204614968 creator A5017742394 @default.
• W3204614968 creator A5028378271 @default.
• W3204614968 creator A5030252089 @default.
• W3204614968 creator A5036529789 @default.
• W3204614968 creator A5038444881 @default.
• W3204614968 creator A5038522274 @default.
• W3204614968 creator A5045013548 @default.
• W3204614968 creator A5047321460 @default.
• W3204614968 creator A5052717155 @default.
• W3204614968 creator A5060904580 @default.
• W3204614968 creator A5064365084 @default.
• W3204614968 creator A5078778688 @default.
• W3204614968 creator A5079346299 @default.
• W3204614968 creator A5081724322 @default.
• W3204614968 creator A5084933406 @default.
• W3204614968 creator A5090061936 @default.
• W3204614968 creator A5091863505 @default.
• W3204614968 date "2021-09-01" @default.
• W3204614968 modified "2023-10-16" @default.
• W3204614968 title "Dogmas, challenges, and promises in phase III allergen immunotherapy studies" @default.
• W3204614968 cites W1132113666 @default.
• W3204614968 cites W1481876993 @default.
• W3204614968 cites W1524200221 @default.
• W3204614968 cites W1608841786 @default.
• W3204614968 cites W1922306607 @default.
• W3204614968 cites W1974675198 @default.
• W3204614968 cites W1986235780 @default.
• W3204614968 cites W1990684266 @default.
• W3204614968 cites W1997729446 @default.
• W3204614968 cites W2007741297 @default.
• W3204614968 cites W2009218973 @default.
• W3204614968 cites W2030393991 @default.
• W3204614968 cites W2040804066 @default.
• W3204614968 cites W2058014154 @default.
• W3204614968 cites W2062838995 @default.
• W3204614968 cites W2071946875 @default.
• W3204614968 cites W2072351435 @default.
• W3204614968 cites W2074474404 @default.
• W3204614968 cites W2081257528 @default.
• W3204614968 cites W2093792384 @default.
• W3204614968 cites W2105385767 @default.
• W3204614968 cites W2121760095 @default.
• W3204614968 cites W2132844265 @default.
• W3204614968 cites W2132851798 @default.
• W3204614968 cites W2156172984 @default.
• W3204614968 cites W2157903425 @default.
• W3204614968 cites W2267191346 @default.
• W3204614968 cites W2271602246 @default.
• W3204614968 cites W2553303016 @default.
• W3204614968 cites W2585773786 @default.
• W3204614968 cites W2588697122 @default.
• W3204614968 cites W2588728005 @default.
• W3204614968 cites W2592507630 @default.
• W3204614968 cites W2770000934 @default.
• W3204614968 cites W2773607015 @default.
• W3204614968 cites W2790503589 @default.
• W3204614968 cites W2803037336 @default.
• W3204614968 cites W2803153151 @default.
• W3204614968 cites W2883695111 @default.
• W3204614968 cites W2902055234 @default.
• W3204614968 cites W2902225700 @default.
• W3204614968 cites W2908541303 @default.
• W3204614968 cites W2916199387 @default.
• W3204614968 cites W2919059895 @default.
• W3204614968 cites W2943914831 @default.
• W3204614968 cites W2952465403 @default.
• W3204614968 cites W2960580696 @default.
• W3204614968 cites W2996829827 @default.
• W3204614968 cites W3007099978 @default.
• W3204614968 cites W3016263844 @default.
• W3204614968 cites W3016737984 @default.
• W3204614968 cites W3039694972 @default.
• W3204614968 doi "https://doi.org/10.1016/j.waojou.2021.100578" @default.
• W3204614968 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8487954" @default.
• W3204614968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34659627" @default.
• W3204614968 hasPublicationYear "2021" @default.
• W3204614968 type Work @default.
• W3204614968 sameAs 3204614968 @default.
• W3204614968 citedByCount "2" @default.
• W3204614968 countsByYear W32046149682022 @default.
• W3204614968 countsByYear W32046149682023 @default.
• W3204614968 crossrefType "journal-article" @default.
• W3204614968 hasAuthorship W3204614968A5006632216 @default.
• W3204614968 hasAuthorship W3204614968A5006791916 @default.
• W3204614968 hasAuthorship W3204614968A5010870367 @default.
• W3204614968 hasAuthorship W3204614968A5017742394 @default.
• W3204614968 hasAuthorship W3204614968A5028378271 @default.
• W3204614968 hasAuthorship W3204614968A5030252089 @default.
• W3204614968 hasAuthorship W3204614968A5036529789 @default.
• W3204614968 hasAuthorship W3204614968A5038444881 @default.
• W3204614968 hasAuthorship W3204614968A5038522274 @default.
• W3204614968 hasAuthorship W3204614968A5045013548 @default.
• W3204614968 hasAuthorship W3204614968A5047321460 @default.

• next